

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:)	Confirmation No.: 8809
)	
Stephen P. MASSIA et al)	Examiner: Ronald T. Niebauer
.)	
Serial No. 10/716,293)	Group Art Unit: 1654
)	
Filed: November 17, 2003)	Date: November 16, 2010
)	
For: THERAPEUTIC BIOCONJUGATES)	

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure as set forth in 37 C.F.R. §1.56, Applicants hereby submit the following information in conformance with 37 C.F.R. §§ 1.97 and 1.98. In accordance with the policies of the U.S. Patent and Trademark Office, only copies of newly cited foreign patents and non-patent literature are being submitted.

Applicant wishes to note that the references noted on the attached PTO-1449 were cited by the European Patent Office in counterpart European Patent Application No. 03789801.2 in the Supplementary European Search Report, mailed August 23, 2010.

The undersigned certifies that either each item of information contained in this information disclosure statement was first cited in a communication from a foreign patent office in connection with a counterpart foreign application not more than three (3) months prior to the filing of this statement.

It is requested that the accompanying PTO-1449 be considered and made of record in the above-identified application. To assist the Examiner, the documents are listed on the attached form PTO-1449. It is respectfully requested that an Examiner initial a copy of this form be returned to the undersigned.

The Commissioner is hereby authorized to charge any fees connected with this filing which may be required now, or credit any overpayment to Deposit Account No. 19-2380.

Respectfully submitted,

By: /Mary S. Webster, Reg. 37,156/
Mary S. Webster

NIXON PEABODY LLP
Suite 900
401 9th Street, N.W.
Washington, DC 20004-2128
Telephone: (202) 585-8000